A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

This study has been completed.

Sponsored by:	Genzyme
Information provided by:	Genzyme
ClinicalTrials.gov Identifier:	NCT00131326

Purpose

This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Condition	Intervention	Phase
Osteoarthritis, Hip Musculoskeletal Diseases	Device: Synvisc (hylan G-F 20)	Phase III

MedlinePlus related topics: Osteoarthritis

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Further study details as provided by Genzyme:

Primary Outcome Measures:

Study Start Date:	November 2003
Estimated Study Completion Date:	April 2006

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00131326

Sponsors and Collaborators

Genzyme

Investigators

Study Director:

David Perkins

Genzyme

More Information

Study ID Numbers:	SYNV-004-02
Study First Received:	August 17, 2005
Last Updated:	May 19, 2008
ClinicalTrials.gov Identifier:	NCT00131326
Health Authority:	United States: Food and Drug Administration

Keywords provided by Genzyme:

osteoarthritis of the hip
Musculoskeletal Diseases

Study placed in the following topic categories:

Musculoskeletal Diseases
Methylprednisolone
Osteoarthritis
Joint Diseases
Arthritis
Prednisolone

Methylprednisolone acetate
Prednisolone acetate
Rheumatic Diseases
Osteoarthritis, Hip
Methylprednisolone Hemisuccinate

ClinicalTrials.gov processed this record on January 16, 2009